bubbafrombama
04-13-2010, 04:30 PM
Here's an interesting twist on the "Power PCT" over on MD's forums. After studying this over a bit, as well as info from a few other sources, I've decided I'm going to try this PCT after my next cycle. I'll keep everyone informed.
I'm also going to run 1000mg of HCG weekly (500mg x 2), as well as 12.5 to 25mg of Aromasin every day (possibly EOD). I'll determine which dose of Aromasin I need based on bloodwork during the cycle. I want to keep my estro in-check, preferably in the 10-25pg/ml range.
***Edit: Please see heavyiron's new amended protocol on post #33 of above thread (also quoted below):
http://forums.musculardevelopment.com/showthread.php/66354-POST-CYCLE-THERAPY?p=1624483&viewfull=1#post1624483
I have changed my thinking in the last few days on the use of Nolva Post Cycle. I am ammending the PCT thread to explain why.
I now strongly believe that an AI should be used as long as there is an aromatizing compound being administered. In this case Testosterone and HCG aromatize therefore using an AI until these meds clear is now what I am recommending. There is some evidence that adding Nolva to an AI does not increase the effectiveness of estro control therefore Nolva has no real advantage alongside an AI unless one is experiencing gyno. Additionally Nolva has been shown to reduce IGF-1 and GH levels. This is not a big deal on cycle as testosterone increases IGF-1 in a dose dependant relationship. However off cycle this is a problem. PCT is a fragile time and lower IGF-1 and GH levels is not desireable as I am sure you can appreciate. The last few days I have been relooking at AI's to find one that is specific to men that can be used on cycle and during PCT. It is my conclusion that Aromasin is the obvious choice.
Aromasin (Exemestane) is a Type-I aromatase inhibitor, or suicidal aromatase inhibitor. It’s called this because it lowers estrogen production in the body by attaching to the aromatase enzyme, and permanently deactivating it. (1)
Personally, I find this to be a very interesting mechanism of action when compared to type-II aromatase inhibitors, which bind competitively to the aromatase enzyme, and eventually unbind, rendering it active again. In the case of Aromasin, this doesn’t happen, and once it does its job on the enzyme, those particular enzymes will no longer function.
Because the enzyme is permanently deactivated there is no estrogen rebound with Aromasin. Estrogen rebound at this critical time during PCT is undesirable so using Arimidex would be inferior. Therefore I believe Aromasin is the AI of choice during PCT.
Reference:
1. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.Br J Clin Pharmacol. 2005 Mar;59(3):355-64.
The following is a study done in men with Aromasin that shows significant effect on estrogen and testosterone;
Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males
Suppression of estrogen, via estrogen receptor or aromatase blockade, is being investigated in the treatment of different conditions. Exemestane (Aromasin) is a potent and selective irreversible aromatase inhibitor. To characterize its suppression of estrogen and its pharmacokinetic (PK) properties in males, healthy eugonadal subjects (14–26 yr of age) were recruited. In a cross-over study, 12 were randomly assigned to 25 and 50 mg exemestane daily, orally, for 10 d with a 14-d washout period. Blood was withdrawn before and 24 h after the last dose of each treatment period. A PK study was performed (n = 10) using a 25-mg dose. Exemestane suppressed plasma estradiol comparably with either dose [25 mg, 38% (P 0.002); 50 mg, 32% (P 0.008)], with a reciprocal increase in testosterone concentrations (60% and 56%; P 0.003 for both). Plasma lipids and IGF-I concentrations were unaffected by treatment. The PK properties of the 25-mg dose showed the highest exemestane concentrations 1 h after administration, indicating rapid absorption. The terminal half-life was 8.9 h. Maximal estradiol suppression of 62 ± 14% was observed at 12 h. The drug was well tolerated. In conclusion, exemestane is a potent aromatase inhibitor in men and an alternative to the choice of available inhibitors. Long-term efficacy and safety will need further study.
full study;
http://jcem.endojournals.org/cgi/content/full/88/12/5951?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&fulltext=estrogen+male+muscle+metabolism&andorexactfulltext=and&searchid=1&FIRSTINDEX=70&sortspec=relevance&resourcetype=HWCIT
I now recommend the following PCT protocol for esters like Cypionate and Enanthate;
Day 1-16 : 2500iu HCG every other day. (You may use less HCG if your testes are normal in size AND you have been using HCG on cycle. ie I have decided upon 1,000iu eod for myself)
100/100/100/50 Clomid (50mg taken twice per day weeks 1-3)
25mg/25mg/25mg/12.5mg Aromasin (25mg daily for 3 weeks)
3g Vit C every day split in 3 doses
10g creatine daily
~heavyiron~
I'm also going to run 1000mg of HCG weekly (500mg x 2), as well as 12.5 to 25mg of Aromasin every day (possibly EOD). I'll determine which dose of Aromasin I need based on bloodwork during the cycle. I want to keep my estro in-check, preferably in the 10-25pg/ml range.
***Edit: Please see heavyiron's new amended protocol on post #33 of above thread (also quoted below):
http://forums.musculardevelopment.com/showthread.php/66354-POST-CYCLE-THERAPY?p=1624483&viewfull=1#post1624483
I have changed my thinking in the last few days on the use of Nolva Post Cycle. I am ammending the PCT thread to explain why.
I now strongly believe that an AI should be used as long as there is an aromatizing compound being administered. In this case Testosterone and HCG aromatize therefore using an AI until these meds clear is now what I am recommending. There is some evidence that adding Nolva to an AI does not increase the effectiveness of estro control therefore Nolva has no real advantage alongside an AI unless one is experiencing gyno. Additionally Nolva has been shown to reduce IGF-1 and GH levels. This is not a big deal on cycle as testosterone increases IGF-1 in a dose dependant relationship. However off cycle this is a problem. PCT is a fragile time and lower IGF-1 and GH levels is not desireable as I am sure you can appreciate. The last few days I have been relooking at AI's to find one that is specific to men that can be used on cycle and during PCT. It is my conclusion that Aromasin is the obvious choice.
Aromasin (Exemestane) is a Type-I aromatase inhibitor, or suicidal aromatase inhibitor. It’s called this because it lowers estrogen production in the body by attaching to the aromatase enzyme, and permanently deactivating it. (1)
Personally, I find this to be a very interesting mechanism of action when compared to type-II aromatase inhibitors, which bind competitively to the aromatase enzyme, and eventually unbind, rendering it active again. In the case of Aromasin, this doesn’t happen, and once it does its job on the enzyme, those particular enzymes will no longer function.
Because the enzyme is permanently deactivated there is no estrogen rebound with Aromasin. Estrogen rebound at this critical time during PCT is undesirable so using Arimidex would be inferior. Therefore I believe Aromasin is the AI of choice during PCT.
Reference:
1. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.Br J Clin Pharmacol. 2005 Mar;59(3):355-64.
The following is a study done in men with Aromasin that shows significant effect on estrogen and testosterone;
Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males
Suppression of estrogen, via estrogen receptor or aromatase blockade, is being investigated in the treatment of different conditions. Exemestane (Aromasin) is a potent and selective irreversible aromatase inhibitor. To characterize its suppression of estrogen and its pharmacokinetic (PK) properties in males, healthy eugonadal subjects (14–26 yr of age) were recruited. In a cross-over study, 12 were randomly assigned to 25 and 50 mg exemestane daily, orally, for 10 d with a 14-d washout period. Blood was withdrawn before and 24 h after the last dose of each treatment period. A PK study was performed (n = 10) using a 25-mg dose. Exemestane suppressed plasma estradiol comparably with either dose [25 mg, 38% (P 0.002); 50 mg, 32% (P 0.008)], with a reciprocal increase in testosterone concentrations (60% and 56%; P 0.003 for both). Plasma lipids and IGF-I concentrations were unaffected by treatment. The PK properties of the 25-mg dose showed the highest exemestane concentrations 1 h after administration, indicating rapid absorption. The terminal half-life was 8.9 h. Maximal estradiol suppression of 62 ± 14% was observed at 12 h. The drug was well tolerated. In conclusion, exemestane is a potent aromatase inhibitor in men and an alternative to the choice of available inhibitors. Long-term efficacy and safety will need further study.
full study;
http://jcem.endojournals.org/cgi/content/full/88/12/5951?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&fulltext=estrogen+male+muscle+metabolism&andorexactfulltext=and&searchid=1&FIRSTINDEX=70&sortspec=relevance&resourcetype=HWCIT
I now recommend the following PCT protocol for esters like Cypionate and Enanthate;
Day 1-16 : 2500iu HCG every other day. (You may use less HCG if your testes are normal in size AND you have been using HCG on cycle. ie I have decided upon 1,000iu eod for myself)
100/100/100/50 Clomid (50mg taken twice per day weeks 1-3)
25mg/25mg/25mg/12.5mg Aromasin (25mg daily for 3 weeks)
3g Vit C every day split in 3 doses
10g creatine daily
~heavyiron~